Orphan & Rare Disease Track Opening Remarks by William Campbell, Executive Vice President & Chief Commercial Officer, CSL Behring
Defining and differentiating value in the rare disease space is critical to ensuring access to patients. How should decisions around access and coverage be guided by value to patients? What is needed to maintain an innovative environment and investments that produce value for patients while also considering stakeholder concerns around cost? Join a robust discussion with experts who will discuss new and innovative approaches to value in the healthcare system while ensuring access to patients.
Ability Level: Intermediate
Session ID: 45181